NMAD

Nomad Power Solutions Inc

4.05

Aug 14 • 3:59 PM ET 0.00 (0.00%)

4.01

Aftermarket • 5:50 PM ET -0.04 (-0.99%)

Industrials Electrical Equipment & Parts USA Micro NASD

Aug 14, 8:40 AMNomad Power Solutions completes acquisition of NOMAD Transportable Power Systems, outlines shift to AI energy infrastructure sector

Peers: STI CBAT ULBI NVX OESX ZOOZ APWC PPSI GWH TGEN

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	76.83M
Enterprise Value	66.34M
Income	-8.72M
Sales	0.00M
Book/sh	1.55
Cash/sh	0.67
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	3
IPO	Sep 21, 2007

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.61
P/C	6.06
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	12.87
Current Ratio	12.87
Debt/Eq	0.05
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-1.00
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	31.98% 15.39%
Sales past 3/5Y	- -
EPS Y/Y TTM	22.50%
Sales Y/Y TTM	-
EPS Q/Q	43.07%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	34.14%
Insider Trans	0.00%
Inst Own	10.39%
Inst Trans	-
ROA	-62.04%
ROE	-70.31%
ROIC	-35.87%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-5.70%
SMA50	-29.96%
SMA200	-6.15%
Trades

Shs Outstand	15.42M
Shs Float	12.49M
Short Float	7.71%
Short Ratio	2.45
Short Interest	0.96M
52W High	8.38 -51.66%
52W Low	2.36 71.61%
Volatility	13.05% 13.52%
ATR (14)	0.60
RSI (14)	41.96
Beta	1.29
Rel Volume	0.35
Avg Volume	392.48K
Volume	137,098

Perf Week	12.50%
Perf Month	-24.86%
Perf Quarter	-19.64%
Perf Half Y	29.81%
Perf YTD	3.05%
Perf Year	3.85%
Perf 3Y	58.82%
Perf 5Y	-81.92%
Perf 10Y	-77.50%
Recom	-
Target Price	-
Prev Close	4.05
Price	4.05
Change %	0.00%

Aug-14-26 08:35AM	NOMAD POWER SOLUTIONS FILES 2026 SECOND QUARTER FORM 10-Q, PROVIDES BUSINESS UPDATE (GlobeNewswire)
Jul-31-26 08:30AM	NOMAD Power Solutions Announces Options Trading Begins on Cboe Options Exchange (GlobeNewswire) +7.43%
Jul-29-26 08:30AM	NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative (GlobeNewswire) -9.26%
Jul-27-26 09:00AM	The AI Buildout Has a Power Problem, and the Grid Is Not Going to Solve It in Time (PR Newswire) -8.06%
07:14AM	Crypto Treasury Firms Pivot to AI in Bid to Win Back Investors (Bloomberg)
09:00AM	Loading…
Jul-15-26 09:00AM	The AI Boom Ran Into a Power Wall; This Nasdaq Company Is Building the Battery That Rolls In to Fix It (PR Newswire)
08:30AM	NOMAD Power Solutions Strengthens Subsidiary Executive Leadership (GlobeNewswire)
Jul-08-26 08:30AM	NOMAD Increases Voyager Fleet Energy Storage by up to 56%, Bringing Eagle and Falcon to 2.025 MWh (GlobeNewswire) +13.61%
Jul-06-26 11:40AM	AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD (PR Newswire)
08:30AM	LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD (GlobeNewswire)
Jul-02-26 08:30AM	LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS (GlobeNewswire) -6.00%
Jun-26-26 08:30AM	LIXTE Joins Russell Microcap Index (GlobeNewswire) +8.12%
Jun-18-26 08:30AM	LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026 (GlobeNewswire) +9.34%
Jun-12-26 08:59AM	From Cancer Drugs to Kilowatts: A NASDAQ Company's Bet on the AI Power Crunch (PR Newswire) -14.62%
08:30AM	LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS) (GlobeNewswire)
08:30AM	Loading…
Jun-03-26 08:30AM	LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth (GlobeNewswire)
Jun-01-26 08:50AM	LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors (GlobeNewswire) +15.36%
May-14-26 05:18PM	LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update (GlobeNewswire)
Apr-27-26 02:14PM	LIXTE Biotechnology Holdings (LIXT) Unlocking New Potential in Precision Cancer Treatment (NewMediaWire)
Apr-20-26 03:00PM	LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape (NewMediaWire)
Apr-17-26 03:30PM	Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built (NewMediaWire) +12.11%
Apr-13-26 03:30PM	LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference (NewMediaWire)
08:00AM	Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference (GlobeNewswire)
Apr-10-26 03:00PM	Lixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic Partnerships (NewMediaWire) +5.17%
Apr-02-26 02:30PM	LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational Year (NewMediaWire)
Apr-01-26 02:30PM	LIXTE Biotechnology (LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes (NewMediaWire)
Mar-31-26 03:45PM	LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year (GlobeNewswire)
03:00PM	LIXTE Biotechnology (LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials (NewMediaWire)
Mar-27-26 03:30PM	Lixte Biotech (LIXT) Advances Precision Oncology With LB-100, Strengthens Position Through Liora Technologies Partnership (NewMediaWire)
Mar-25-26 03:00PM	Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (LIXT) Saw It Coming (NewMediaWire) +10.74%
03:00PM	Loading…
Mar-23-26 03:00PM	LIXTE Biotechnology (LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape (NewMediaWire)
Mar-10-26 02:26PM	LIXTE Biotechnology Holdings (LIXT) Adds Innovative LiGHT Therapy to Pipeline (NewMediaWire)
Mar-09-26 03:00PM	LIXTE Biotechnology (LIXT) Advances Lead Compound in Tumor Immunogenicity Research (NewMediaWire)
Feb-18-26 03:00PM	LIXTE Biotechnology (LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary (NewMediaWire)
08:00AM	LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary (GlobeNewswire)
Feb-12-26 03:00PM	LIXTE Biotechnology (LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy (NewMediaWire)
Feb-10-26 03:00PM	LIXTE Biotechnology (LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment (NewMediaWire) -9.73%
Feb-09-26 03:30PM	LIXTE Biotechnology (LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment (NewMediaWire)
Feb-05-26 02:30PM	Improving the Odds: How LIXTE Biotechnology (LIXT) Is Working to Make Cancer Therapies More Effective (NewMediaWire) -6.21%
Jan-23-26 03:00PM	LIXTE Biotechnology Holdings (LIXT) Advances a Novel Approach to Enhancing Cancer Therapy (NewMediaWire)
Jan-21-26 03:30PM	LIXTE Biotechnology Holdings (LIXT) Sponsors Good Health Mind, Body and Soul Summit (NewMediaWire)
08:00AM	DE LA SOUL-LED "GOOD HEALTH SUMMIT" LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE (GlobeNewswire)
Jan-20-26 08:00AM	LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29 (GlobeNewswire) -8.43%
Jan-08-26 03:50PM	LIXTE Biotechnology Holdings (LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK (NewMediaWire)
Dec-23-25 08:00AM	LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial (GlobeNewswire)
Dec-18-25 09:00AM	Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules (GlobeNewswire)
Dec-08-25 08:30AM	LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities (ACCESSWIRE) +7.16%
Dec-03-25 11:00AM	LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology (ACCESSWIRE)
08:00AM	LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers (ACCESSWIRE)
Nov-25-25 08:30AM	LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment (GlobeNewswire) -8.50%
Oct-29-25 08:00AM	LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3 (GlobeNewswire)
Oct-16-25 08:00AM	LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans (GlobeNewswire)
Sep-16-25 08:30AM	LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT) (ACCESSWIRE)
Sep-15-25 05:40PM	LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT) (ACCESSWIRE) -5.08%
Sep-10-25 04:05PM	LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions (GlobeNewswire) +6.25%
Sep-05-25 08:35AM	24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor (Newsfile)
Sep-03-25 08:00AM	LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer (GlobeNewswire) +11.59%
Aug-27-25 08:15AM	24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy (GlobeNewswire)
Aug-25-25 08:05AM	24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets (GlobeNewswire)
Aug-19-25 11:18AM	24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the "Too Much of a Good Thing" Strategy for LB-100 (GlobeNewswire) -8.90%
Aug-18-25 08:00AM	LIXTE Biotechnology Holdings Provides Corporate Update (GlobeNewswire) +6.41%
Aug-14-25 09:06PM	24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025 (GlobeNewswire) -7.95%
08:05AM	24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025 (GlobeNewswire)
Aug-13-25 08:49AM	24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy (GlobeNewswire) -16.29%
07:30AM	LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency (GlobeNewswire)
Jul-16-25 08:05AM	LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements (GlobeNewswire)
Jul-09-25 05:15PM	Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.s $1.5 Million Registered Direct Offering (GlobeNewswire) +8.70% +53.45%
08:05AM	New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials (GlobeNewswire)
Jul-08-25 04:05PM	Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering (GlobeNewswire) +12.95%
02:57PM	Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.s $5.0 Million Private Placement (GlobeNewswire)
Jul-02-25 04:05PM	Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market (GlobeNewswire) +71.19% +40.10%
Jul-01-25 04:15PM	Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market (GlobeNewswire) +30.39%
Mar-31-25 08:30AM	LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 (GlobeNewswire)
Mar-27-25 08:30AM	LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer (GlobeNewswire)
Mar-10-25 08:30AM	New Findings Show how LIXTE's Lead Clinical Compound, LB-100, is Metabolized to its Active Form (GlobeNewswire)
Feb-25-25 08:30AM	LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer (GlobeNewswire) +15.36%
Feb-14-25 10:43AM	Lixte Biotechnology announces closing of $1.05M registered direct offering (TipRanks)
Feb-13-25 10:35AM	LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -17.65%
Feb-11-25 08:42AM	LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -15.35%
Feb-10-25 05:00PM	LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement (GlobeNewswire) -7.32%
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE)
Sep-04-24 08:30AM	LIXTE Receives U.S. Patent Issue Notification for Immune Oncology (GlobeNewswire)
Aug-26-24 08:30AM	First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company (GlobeNewswire) +11.12%
Aug-19-24 08:30AM	LIXTE Biotechnology Provides Update On Recent Activities and Developments (GlobeNewswire)
Aug-16-24 08:53PM	LIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q2 2024 (InvestorPlace)
Aug-15-24 08:30AM	LIXTE Biotechnology Holdings to Present at Two Investor Conferences (GlobeNewswire)
Aug-14-24 10:50PM	Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event (ACCESSWIRE)
Jun-14-24 11:00AM	LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial (GlobeNewswire)
09:30AM	LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial (GlobeNewswire)
Jun-06-24 08:30AM	Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System (GlobeNewswire)
Jun-03-24 08:30AM	LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer (GlobeNewswire) +6.50%
May-20-24 08:30AM	LIXTE Biotechnology Holdings Provides Update on Recent Activities (GlobeNewswire)
May-09-24 01:53PM	LIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q1 2024 (InvestorPlace)
May-08-24 09:25AM	LIXTE Biotechnology Co-Sponsoring International Scientific Conference on Therapeutic Over-Activation in Cancer (GlobeNewswire)
Mar-27-24 08:30AM	NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES (GlobeNewswire) +56.10%
Mar-21-24 08:30AM	LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments (GlobeNewswire)
Feb-27-24 08:30AM	Professor Ren Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research (GlobeNewswire) +20.81%
Feb-26-24 08:30AM	LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI (GlobeNewswire)
Jan-29-24 08:30AM	First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial (GlobeNewswire) +8.04%
Nov-13-23 08:30AM	LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations (GlobeNewswire)

Nomad Power Solutions, Inc. engages in providing an AI energy infrastructure equipment and services platform. It focuses on delivering scalable, reliable, and efficient power generation and energy solutions. The company was founded on May 24, 2005 and is headquartered in Waterbury, VT.

Chairman of the Board of DirectorsMr. Geordan G. Pursglove

Chief Financial OfficerMr. Peter M. Stazzone

Chief Operating OfficerMr. Chris McKay

Director of SalesMr. Jim Allan CFA

Chief of Product & VP of OperationsMs. Huda Almashhadany

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NMAD

Nomad Power Solutions Inc

Upgrade your Finviz experience